Please 

  Don't point out me and say, this is the ...tard who is summarizing the most serious subjects and also not say he is crying like a baby for suggesting the critics a treatment model for Covid and nobody responded him. 

  These are not true. Besides the two of the articles, I have summarized was about health but I will not always write about health. I will just summarize the great articles for my taste. I am getting a bit exhausted making a concrete summary so if you think the article seems like written by AI or you think it lacks please reach out to me, but please only get angry at me after reading the whole summary. You might start saying now I wish I have read the article in the first place, so here is my summary of a fancy article:

  This is one of the best gifts I can give to you. Free money from a global company. When you sign up for free you will get $100 and when you refer the site to your friend you will get $200 each immediately. 

  Just mail me at mertatakan53@gmail.com P.S If you are extremely rich enough to not taking these free 1000s of dollars, I can be your ugly bodyguard protecting you from stock exchanges.

  ""You may be surprised to learn that of the trio of long-awaited coronavirus vaccines, the most promising, Moderna’s mRNA-1273, which reported a 94.5 percent efficacy rate on November 16, had been designed by January 13. It was completed before China had even acknowledged that the disease could be transmitted from human to human, more than a week before the first confirmed coronavirus case in the United States. 

  

  Could things have moved faster from design to deployment? “Operation Warp Speed” meant running clinical trials simultaneously rather than sequentially, manufacturing the vaccine at the same time. McKeown hypothesis — that medical interventions tend to play only a small role compared to public-health measures, socioeconomic advances, and the natural dynamics of the disease as it spreads through a population. 

  Redfield believes there may be 200,000 more American deaths to come. A half a million American lives would have been lost in the interim. Around the world, considerably more. Just one drug, the steroid dexamethasone, has proven to be a worthwhile treatment for COVID-19 in a randomized control trial — though given too early, it too can be dangerous. 

  Balloux told me recently, can be attributed to doctors no longer trying so many experimental treatments and focusing instead on the basic, old-fashioned job of simply keeping patients alive. The treatment dilemmas facing physicians and patients in the early stages of a novel pandemic are, of course, not the same as the dilemma of rushing a new vaccine to a still-healthy population. But on other matters of population-level guidance, our messaging about risk has been erratic all year, too. 

  The whole time, we also knew that the Moderna vaccine was essentially safe. We were just waiting to know for sure that it worked, too. Which has made a number of them wonder whether, in the future, at least, we might find a way to do things differently — without even thinking in terms of trade-offs. But the scientists I spoke to about the way this pandemic may reshape future vaccine development were more focused on how to accelerate or skip Phase I, which tests for safety. 

  Scientists have a very clear sense of which virus families have pandemic potential, and given the resemblance of those viruses, can develop not only vaccines for all of them but also ones that could easily be tweaked to respond to new variants within those families. In total, he estimates, the research and clinical trials necessary to do this would cost between $1 billion and $3 billion. So far this year, the U.S. government has spent more than $4 trillion on pandemic relief. When he compares the cost of such a project to the Pentagon’s F-35 — you could build vaccines for five potential pandemics for the cost of a single plane, and vaccines for all of them for a fraction of the cost of that fighter-jet program as a whole — he isn’t signaling confidence it will happen, but the opposite. 

  “You can make antigens in the research center and just test it — that’s pretty inexpensive.” And if a Phase III trial were deemed necessary, it could start just weeks after the disease was identified and conclude in as soon as ten weeks.